ImmusanT: Having their cake

ImmusanT's vaccine could allow celiac patients to eat normally

ImmusanT Inc. is developing what could be the first treatment for celiac disease that allows patients to eat a normal diet. The company's Nexvax2 vaccine seeks to reprogram CD4+ T cells to induce gluten tolerance.

The biotech also is developing a blood-based companion diagnostic. Both programs were acquired from Nexpep Pty. Ltd., which is now a shell company.

Celiac disease is an immune-mediated disorder triggered by consumption of foods containing gluten, which is broken into immunogenic peptides that are allowed to pass through the intestinal epithelium.

The peptides are

Read the full 869 word article

How to gain access

Continue reading with a
two-week free trial.